Shanghai Henlius gets CSRC nod for equity issue
Hong Kong-listed Shanghai Henlius Biotech has won approval from the Mainland securities regulator to sell a chunk of new shares.
Unlock this article.
The content you are trying to view is exclusive to our subscribers.
To unlock this article: